BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31454442)

  • 1. Identification of new octamer transcription factor 1-target genes upregulated in castration-resistant prostate cancer.
    Yamamoto S; Takayama KI; Obinata D; Fujiwara K; Ashikari D; Takahashi S; Inoue S
    Cancer Sci; 2019 Nov; 110(11):3476-3485. PubMed ID: 31454442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
    Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
    BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative Genomic Analysis of OCT1 Reveals Coordinated Regulation of Androgen Receptor in Advanced Prostate Cancer.
    Takayama KI; Suzuki Y; Yamamoto S; Obinata D; Takahashi S; Inoue S
    Endocrinology; 2019 Feb; 160(2):463-472. PubMed ID: 30649323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
    Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
    Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
    Shafran JS; Andrieu GP; Györffy B; Denis GV
    Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
    Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
    Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Regulatory effect of Skp2 on the expression and transactivation of the androgen receptor in the progression of castration-resistant prostate cancer].
    Song YT; Wu KJ; Wang XY; Na YG; Yin CM
    Zhonghua Nan Ke Xue; 2016 Feb; 22(2):122-7. PubMed ID: 26939395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer.
    Obinata D; Takayama K; Urano T; Murata T; Kumagai J; Fujimura T; Ikeda K; Horie-Inoue K; Homma Y; Ouchi Y; Takahashi S; Inoue S
    Int J Cancer; 2012 Mar; 130(5):1021-8. PubMed ID: 21387309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
    Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
    Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC.
    Arai T; Okato A; Yamada Y; Sugawara S; Kurozumi A; Kojima S; Yamazaki K; Naya Y; Ichikawa T; Seki N
    Cancer Med; 2018 May; 7(5):1988-2002. PubMed ID: 29608247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: Regulation of NCAPH by antitumor miR-199a/b-3p.
    Arai T; Kojima S; Yamada Y; Sugawara S; Kato M; Yamazaki K; Naya Y; Ichikawa T; Seki N
    Int J Urol; 2019 Apr; 26(4):506-520. PubMed ID: 30818424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OCT1 Is a Poor Prognostic Factor for Breast Cancer Patients and Promotes Cell Proliferation via Inducing NCAPH.
    Ogura T; Azuma K; Sato J; Kinowaki K; Takayama KI; Takeiwa T; Kawabata H; Inoue S
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
    Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
    Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer.
    Obinata D; Funakoshi D; Takayama K; Hara M; Niranjan B; Teng L; Lawrence MG; Taylor RA; Risbridger GP; Suzuki Y; Takahashi S; Inoue S
    Sci Rep; 2022 Apr; 12(1):6094. PubMed ID: 35413990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
    Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
    Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.